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abstract
PURPOSE The treatment of chronic lymphocytic leukemia (CLL) has been revolutionized by targeted therapies that
either inhibit proliferation (ibrutinib) or reactivate apoptosis (venetoclax). Both significantly improve survival in CLL
and replace chemoimmunotherapy for many patients. However, individually, they rarely lead to eradication of
measurable residual disease (MRD) and usually are taken indefinitely or until progression. We present the CLARITY
trial that combined ibrutinib with venetoclax to eradicate detectable CLL with the intention of stopping therapy.
PATIENTS AND METHODS CLARITY is a phase II trial that combined ibrutinib with venetoclax in patients with
relapsed or refractory CLL. The primary end point was eradication of MRD after 12 months of combined therapy.
Key secondary end points were response by International Workshop on CLL criteria, safety, and progression-free
and overall survival.
RESULTS In 53 patients after 12 months of ibrutinib plus venetoclax, MRD negativity (fewer than one CLL cell in
10,000 leukocytes) was achieved in the blood of 28 (53%) and the marrow of 19 (36%). Forty-seven patients
(89%) responded, and 27 (51%) achieved a complete remission. After a median follow-up of 21.1 months, one
patient progressed, and all patients were alive. A single case of biochemical tumor lysis syndrome was observed.
Other adverse effects were mild and/or manageable and most commonly were neutropenia or GI events.
CONCLUSION The combination of ibrutinib plus venetoclax was well tolerated in patients with relapsed or re-
fractory CLL. There was a high rate of MRD eradication that led to the cessation of therapy in some patients. The
progression-free and overall survival rates are encouraging for relapsed and refractory CLL.
J Clin Oncol 37:2722-2729. © 2019 by American Society of Clinical Oncology
Licensed under the Creative Commons Attribution 4.0 License
INTRODUCTION
Chronic lymphocytic leukemia (CLL) is the most
common hematologic malignancy in the Western
world, with an incidence of six per 100,000 per year.1
A proportion of patients have indolent disease and
never require therapy.2 In contrast, other patients’
disease is more aggressive and results in significant
ill health and reduced life expectancy. The median
survival for the whole CLL population is approximately
10 years from diagnosis. Chemoimmunotherapy (CIT),
such as fludarabine, cyclophosphamide, and rituximab
(FCR) and bendamustine and rituximab (BR), result
in remission in most patients. However, CIT is rarely
curative, and the majority of patients experience re-
lapse and eventually succumb to their disease. CIT
is also associated with toxicity, which leads to signif-
icant immediate and late complications (including
possible death) and limits its use across the whole
patient population.3,4
In CLL, malignant B cells proliferate excessively
through B-cell receptor (BCR)–dependent signaling
and fail to undergo apoptosis efficiently as a result of
overexpression of the anti-apoptotic protein B-cell
lymphoma 2 (Bcl-2). This dual pathophysiology
leads to the accumulation of CLL cells and, thereby,
progressive immune dysfunction and tissue infiltration.
However, the outlook for patients with CLL has im-
proved dramatically with therapies that directly target
components of the BCR signaling pathway,5 particu-
larly Bruton tyrosine kinase (Btk), or apoptosis through
targeting the Bcl-2 protein.
Ibrutinib is an orally bioavailable irreversible inhibitor
of Btk that blocks BCR signaling to prevent CLL
cell proliferation and inhibit CLL cell migration and
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adhesion.6,7 Ibrutinib monotherapy is effective in CLL5 and
leads to rapid reduction in lymphadenopathy and disease
redistribution into the peripheral blood (PB).8-10 Ibrutinib
has been approved by the US Food and Drug Adminis-
tration (FDA) and European Medicines Agency (EMA) as
a single agent for patients with previously untreated and
relapsed CLL and in combination with BR in previously
treated CLL because it leads to a prolongation of both
progression-free and overall survival in both groups.9,11-15
Eradication of detectable CLL with single-agent ibrutinib
is rare, and patients usually remain on ibrutinib indefinitely
or until disease progression.12-15 In addition, ibrutinib leads
to well-documented adverse effects in a proportion of pa-
tients, including diarrhea, fatigue, bruising and hemorrhage,
hypertension, and atrial fibrillation, with approximately 10%
of patients discontinuing the drug as a result.11-13,15
Venetoclax is an orally bioavailable small-molecule inhibitor
of Bcl-2 that leads to CLL cell apoptosis.16,17 Venetoclax
therefore would be expected to sensitize CLL cells to death
by other discrete mechanisms. In early studies, venetoclax
showed unexpected efficacy as monotherapy, with a pro-
portion of patients with high-risk CLL achieving eradication
of measurable residual disease (MRD) to either venetoclax
monotherapy18 or the combination of venetoclax with
rituximab.19 Venetoclax as a single agent is approved by
the FDA for patients with CLL who have received at least
one prior therapy and by the EMA for previously untreated
patients with CLL in the presence of chromosome
del(17p) or TP53 mutations and for patients with re-
lapsed CLL with or without del(17p) or TP53 mutations
who experience treatment failure with a BCR pathway
inhibitor and CIT. Both the FDA and the EMA have ap-
proved venetoclax in combination with rituximab in pa-
tients with relapsed CLL who have received at least one
prior treatment. Venetoclax is generally well tolerated but
can lead to GI adverse effects (nausea and diarrhea) and
neutropenia. The most common adverse events (AEs)
experienced at grade 3 and higher are neutropenia, in-
fection, and anemia.20 Tumor lysis syndrome (TLS) oc-
casionally occurs in the first month of venetoclax, but with
initial dosing commencing at 20 mg/d and ramping up
each week to the full dose of 400 mg/d, biochemical TLS
occurs in 5% of patients, and clinical TLS is rare.20,21
However, the observation that a proportion of patients,
probably approximately 15% with monotherapy,22 achieve
eradication of MRD is encouraging and suggests that pa-
tients may be able to stop venetoclax after a defined duration
of therapy.
Given the dual pathogenesis of CLL, we hypothesized that
the combination of ibrutinib with venetoclax would be
expected to be additive or possibly synergistic and would
lead to a higher proportion of patients achieving an MRD-
negative remission and therefore being able to stop ther-
apy. The CLARITY trial is a phase II single-arm study to
investigate the safety and efficacy of combining ibrutinib
with venetoclax in patients with CLL who have either pro-
gressed during or after conventional CIT (FCR or BR) or for
patients with chromosome del(17p) who have experienced
treatment failure with at least one prior line of therapy.
PATIENTS AND METHODS
Study Conduct
CLARITY is a single-arm, phase II study in 54 patients with
relapsed/refractory CLL. The study was approved by the
National Research Ethics Committee and regulatory review
bodies. The review boards of participating institutions ap-
proved the study protocol (Data Supplement), which was
conducted according to the Declaration of Helsinki and
Good Clinical Practice. All patients provided written in-
formed consent. An independent data monitoring com-
mittee reviewed safety data throughout the trial. The study
was run independently through the National Cancer Re-
search Institute CLL clinical study group and sponsored by
the University of Birmingham. Data were collected by in-
vestigators and analyses conducted by the study statistician
and investigators.
Patients, Investigations, and Treatment
Patients with CLL who required therapy according to the
2008 International Workshop on Chronic Lymphocytic
Leukemia (iwCLL) guidelines,23 who had been treated
previously with CIT (FCR or BR), or who had chromosome
del(17p) and experienced treatment failure with at least
one line of therapy were recruited. Prior treatment with
idelalisib was allowed. Patients previously treated with ei-
ther ibrutinib (or an alternative Btk inhibitor) or venetoclax
were excluded, as were patients with significant comor-
bidity, previous Richter transformation, CNS involvement,
or active autoimmune complications. Creatinine clearance
had to be greater than 50 mL/min. Full eligibility criteria are
provided in the Data Supplement.
AEs were assessed at protocol-specified time points from
day 1 of treatment until 30 days after the end of therapy
according to National Cancer Institute Common Termi-
nology Criteria for Adverse Events (version 4). AEs that met
the definition of seriousness could be reported after the 30-
day cutoff at investigator discretion. Dose modification
guidelines are included in the Data Supplement.
Patients were initially treated with 8 weeks of ibrutinib
monotherapy (420 mg/d). Four patients who discontinued
ibrutinib as a result of toxicity did not start combination
therapy with venetoclax and were replaced. Fifty patients
started venetoclax in combination with ibrutinib on day 1 of
week 9. In the first three patients, venetoclax was added at
a starting dose of 10 mg/d, with a weekly dose ramp-up to
20 mg, 50 mg, 100 mg, 200 mg, and the maximum dose of
400 mg/d. No TLS was seen for these three patients, so
according to the protocol, all subsequent patients began
venetoclax at 20 mg/d. Before starting venetoclax, patients
were assessed for risk of TLS (Data Supplement) and
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categorized as low, medium, or high risk. High-risk patients
were admitted for the first two doses of venetoclax.
PB and bone marrow (BM) MRD assessments, clinical
assessments, and computed tomography (CT) scans were
performed at screening (before ibrutinib), week 8 (before
venetoclax), month 8 (6months of ibrutinib plus venetoclax),
month 14 (12 months of ibrutinib plus venetoclax), and
month 26 (24 months of ibrutinib plus venetoclax). PB and
BM MRD were assessed by highly sensitive multiparameter
flow cytometry using an assay capable of detecting one CLL
cell in 100,000 leukocytes.24 The methods used are de-
scribed in the Data Supplement.
Treatment and End Points
The primary end point of the trial was the eradication of
MRD to fewer than one CLL cell in 10,000 leukocytes
(MRD4) according to the 2008 iwCLL guidelines23 in both
PB and BM after 12 months of ibrutinib plus venetoclax
(month 14). Secondary end points were the eradication
of MRD (below MRD4) in PB and BM after 6 months of
ibrutinib plus venetoclax (month 8) and 24 months of
ibrutinib plus venetoclax (month 26). MRD was assessed in
a single central laboratory (Haematological Malignancy
Diagnostic Service, Leeds, United Kingdom). Other sec-
ondary end points were investigator-assessed response by
iwCLL criteria (including measurement of lymph node re-
sponse by CT scan), progression-free and overall survival,
and toxicity of ibrutinib plus venetoclax.
The duration of therapy was defined by the confirmed MRD
response with the following three possibilities: MRD4 in
both PB and BM atmonth 8 to stop ibrutinib and venetoclax
at month 14, MRD detectable at month 8 but MRD4 in both
PB and BM at month 14 and/or at month 26 to stop ibrutinib
and venetoclax at month 26, and MRD detectable at month
26 to stop venetoclax but continue ibrutinib until progression.
Confirmation ofMRD responsewas clinically defined by three
consecutive PB samples below MRD4, with the last con-
currently confirmed by a BM below MRD4. In addition to
confirmation of MRD response, patients were assessed by
iwCLL 2008 criteria and confirmed to have a complete
response (CR) before stopping therapy.
Statistical Analyses
The primary assumption was that after 12 months of
ibrutinib plus venetoclax, at least 30% of patients would
have MRD eradication (PB and BM) according to iwCLL
criteria23 (MRD4). An A’Hern design25 was used with a one-
sided statistical significance (a) of 2.5% and statistical
power of 95.5% to test the null hypothesis that the rate of
eradication is no greater than 10% against the alternative
that it exceeds 30%. Thus, if at least 10 of 50 patients
achieved MRD eradication in both the PB and the BM, then
the combined treatment would be considered of interest for
additional investigation. Data were frozen on November
5, 2018.
RESULTS
Study Population
Fifty-four patients were recruited from May 2016 to No-
vember 2017 (Table 1). The median number of prior
therapies was one (range, one to six therapies), including
FCR or BR in 45 patients (83%) and idelalisib-containing
treatments in 11 (20%). Eleven (22%) of 50 patients had
del(17p), nine (20%) of 45 patients had del(11q) but not
del(17p), and 40 (75%) of 53 patients had unmutated
IGVH genes. Four patients stopped ibrutinib because of
AEs in the first 8 weeks before starting venetoclax. The
reasons for discontinuation were Aspergillus infection
(brain abscess, grade 3), mucosal infection (grade 1),
TABLE 1. Patient Characteristics
Characteristic Patients, No. (%)
No. of patients 54
Sex
Male 37 (69)
Female 17 (31)
Median age, years (range) 64 (31-83)
Current Binet stage
A 12 (22)
B 18 (33)
C 22 (41)
NK 2 (4)
Lymph nodes, bulky $ 5 cm 4 (7)
ECOG performance status
0 32 (59)
1 18 (33)
2 3 (6)
NK 1 (2)
IGVH gene use
Mutated 10 (19)
Unmutated 40 (74)
VH3-21 3 (6)
Failed 1 (2)
Del(17p) 11 of 50 (22)
Del(11q), not del(17p) 9 of 45 (20)
Median prior therapies (range) 1 (1-6)
Previous FCR or BR 45 of 54 (83)
Del(17p) in those who had previous
FCR or BR
7 of 41 (17)
Previous FCR or BR in those with del(17p) 7 of 11 (64)
Relapse within 3 years of BR or FCR 21 of 54 (39)
Previous idelalisib 11 of 54 (20)
Abbreviations: BR, bendamustine and rituximab; ECOG, Eastern
Cooperative Oncology Group; FCR, fludarabine, cyclophosphamide,
and rituximab; NK, not known; VH, IGVH.
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postural hypotension (grade 2), and multiple intolerances
(grade 1 arthralgia, diarrhea, and dizziness). The remaining
50 patients completed the dose ramp-up of venetoclax
combined with ibrutinib (Data Supplement).
Safety and Tolerability
A single biochemical TLS event (grade 3) was reported with
an increase in both creatinine and phosphate. Dosing of
venetoclax was interrupted until the biochemical abnor-
malities resolved, and the patient subsequently ramped
up to 400 mg/d of venetoclax with no additional TLS. At
the data lock on November 5, 2018, two suspected
unexpected serious adverse reactions, 36 serious AEs, 99
grade 3 or 4 AEs (Tables 2 and 3), and 1,049 AEs (all
grades; Data Supplement) were reported. Of note, there
were nine grade 3 or 4 infections and 34 episodes of grade
3 or 4 neutropenia. Thus far, all serious AEs have resolved
with appropriate management, and all patients remain in
the study after resolution. No AEs have been fatal.
Ibrutinib treatment was interrupted in 28 patients for
a median of 9 days (range, 1 to 80 days) and reduced in
eight patients for a median of 6 days (range, 5 to 121 days).
Venetoclax was interrupted in 23 patients for a median of
8 days (range, 1 to 62 days) and reduced in 11 patients for
a median of 15 days (range, 3 to 78 days). The majority of
treatment modifications for each drug were associated with
toxicity; diarrhea and decreased neutrophil count were the
most frequently cited AEs.
Efficacy
As expected, there was an increase in the level of CLL in PB
(Fig 1) during the first 8 weeks of ibrutinib therapy (median
absolute increase, 27.3 3 109/L; range, 376 3 109/L
decrease to 4043 109/L increase). Figure 1 shows a rapid
response to ibrutinib in all patients, with the level of CLL
dropping rapidly again when venetoclax was added and
a sustained response in all but one patient.
Forty-nine patients had reached the 14-month (12 months
of ibrutinib plus venetoclax) PB, BM, and CT scan as-
sessments at the time of the data freeze. In the analysis of
these patients, and the treatment of the four patients who
did not commence venetoclax as nonresponders, 47 (89%)
of the 53 had an overall response, and 27 (51%) achieved
a CR or CR with incomplete BM recovery. Twenty patients
(38%) achieved a partial response (11 had lymphade-
nopathy [generally small residual nodes on a CT scan], two
had BM involvement, two had no trephine, three were MRD
positive in PB and/or BM, and two were unconfirmed).
The primary end point was the proportion of patients with
MRD-negative BM (defined according to iwCLL criteria as
MRD4 in the BM at month 14 after 12 months of combined
ibrutinib plus venetoclax). This was achieved in 19 (36%) of
53 patients, which thus exceeded the assumption that the
combination would be of interest if an excess of 30% of
patients became MRD negative. Twenty-eight (53%) of 53
patients were MRD negative in the PB at month 14. Thirty-
nine (81%) of 48 patients had no morphologically evident
CLL in the BM biopsy (Table 4). Continuous improvement
was seen in the depth of MRD reduction, with 11 (44%) of
25 patients achieving MRD4 or below by flow cytometry at
month 26 (Fig 2).
At the time of the data freeze, two patients were reported to
have stopped ibrutinib plus venetoclax after confirmation of
MRD-negative remission at month 14. These patients since
have not experienced relapse and remain below MRD4 in
TABLE 2. Grade 3/4 Adverse Events
Adverse Event Grade 3 Grade 4 Total
Anemia 1 0 1
Blood and lymphatic system disorders 2 0 2
Atrial flutter 1 0 1
Heart failure 1 0 1
Left ventricular systolic dysfunction 1 0 1
Myocardial infarction 1 0 1
Eye disorders 1 0 1
Abdominal pain 2 0 2
Dental caries 1 0 1
Diarrhea 4 0 4
Dysphagia 1 0 1
Mucositis oral 1 0 1
Edema limbs 1 0 1
Fatigue 1 0 1
Autoimmune disorder 1 0 1
Infections and infestations 3 0 3
Lung infection 5 0 5
Upper respiratory infection 1 0 1
Injury, poisoning, and procedural
complications
3 0 3
ALT increased 1 0 1
AST increased 1 0 1
Neutrophil count decreased 23 10 33
Platelet count decreased 7 7 14
Metabolism and nutrition disorders 1 0 1
Tumor lysis syndrome 1 0 1
Arthralgia 1 0 1
Headache 3 0 3
Cough 1 0 1
Pneumonitis 0 1 1
Respiratory, thoracic, and mediastinal
disorders
1 0 1
Voice alteration 1 0 1
Skin and subcutaneous tissue disorders 2 0 2
Hypertension 5 0 5
Total 81 18 99
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PB and BM. The remaining patients are continuing therapy
within the trial protocol, including those MRD-negative
patients with residual lymphadenopathy.
After a median follow-up of 21.1 months, only one patient
(adverse IGHV [subset #2/VH3-21], no TP53/ATM deletion,
not MRD negative at any point) has had progressive CLL,
and no patients developed transformed disease. All 50
patients were alive at the latest follow-up (Data Supplement).
DISCUSSION
In a study by Ahn et al26 with a 5-year follow-up, the overall
response rate (ORR) for ibrutinib monotherapy in relapsed
CLL was 83% early in the treatment but increased to
95% with prolonged treatment; this includes a minority of
patients with persistent lymphocytosis, but no patients
achieved an MRD-negative remission after 24 months of
ibrutinib. In another study, the ORR for venetoclax mon-
otherapy in relapsed poor-risk CLL was 82%, with 10% of
patients achieving a CR.27 MRD response for venetoclax
monotherapy in del(17p) CLL was reported by Stilgenbauer
et al22 as 30% MRD negative in the PB at 12 months, but
there were limited BM data for confirmation. The combi-
nation of ibrutinib plus venetoclax has been investigated in
mantle cell lymphoma, with a 71% ORR at week 16 and
75% progression-free survival rate at 12 months, a much
better outcome than reported for ibrutinib or venetoclax
monotherapies in that indication.28
The current results of ibrutinib plus venetoclax after
12 months of combined therapy in a similar patient
TABLE 3. Adverse Events of Interest
CTCAE (version 4) Category Grade 1 Grade 2 Grade 3 Grade 4 Total
Eye hemorrhage 5 0 1 0 6
Bruising/hematoma 2 0 1 0 3
Bleeding/blood blister 7 0 1 0 8
Neutropenia (excluding febrile neutropenia) 0 3 24 10 37
Febrile neutropenia 0 1 0 0 1
Atrial fibrillation/flutter 1 1 1 0 3
Tumor lysis syndrome* 0 0 1 0 1
Total 15 5 29 10 59
Abbreviation: CTCAE, Common Terminology Criteria for Adverse Events.
*A single case of tumor lysis syndrome (at 200 mg dose), with increasing phosphate and creatinine. Managed by delaying venetoclax, which
was rapidly re-escalated with no further tumor lysis syndrome.
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population are encouraging, with 89% of patients responding
to treatment and 51% achieving a CR or CR with incomplete
BM recovery. In addition, 36% of patients achieved an MRD-
negative remission after 12 months of combination therapy,
which is rarely seen with ibrutinib monotherapy and occurs
in a small proportion of patients treated with venetoclax. In
the MURANO (Venetoclax Plus Rituximab Compared With
Bendamustine Plus Rituximab in Relapsed or Refractory
CLL) study, 194 patients with relapsed CLL received
venetoclax plus rituximab with an ORR of 93.3% and a CR
rate of 26.8%; MRD-negative BM was observed in 27.3%
at month 9.29
TABLE 4. Responses
Response Month 14, No. of No. Evaluated (%)
Patient Group CR CRi PR Overall Response PB MRD Negative BM MRD Negative Trephine Normal
All patients 22 of 53 (42) 5 of 53 (9) 20 of 53 (38) 47 of 53 (89) 28 of 53 (53) 19 of 53 (36) 39 of 48 (81)
FCR/BR relapse , 36 months 8 of 21 (38) 2 of 21 (10) 8 of 21 (38) 18 of 21 (86) 14 of 20 (70) 9 of 20 (45) 18 of 19 (95)
Prior idelalisib 3 of 11 (27) 1 of 11 (9) 4 of 11 (36) 8 of 11 (73) 6 of 9 (67) 5 of 9 (56) 7 of 9 (78)
Abbreviations: BM, bone marrow; BR, bendamustine and rituximab; CR, complete response; CRi, with incomplete bone marrow recovery; FCR,
fludarabine, cyclophosphamide, and rituximab; MRD, measurable residual disease (iwCLL criteria, fewer than one CLL cell in 10,000 leukocytes); PB,
peripheral blood; PR, partial response.
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Previous reports have demonstrated that achieving MRD
negativity in CLL with a variety of therapies, including
chemotherapy, immunotherapy, and transplantation, is
associated with improved progression-free and overall
survival, regardless of the therapy used to achieve a re-
sponse.30 In the CLARITY study, ibrutinib plus venetoclax
seems to be effective in achieving MRD eradication in PB
and BM by month 14 in patients with CLL who were re-
fractory to CIT and/or had received prior treatment with
idelalisib regardless of poor prognostic features, such as
chromosome del(17p) or immunoglobulin mutation status.
In CLARITY, only one patient progressed, and all patients
were alive at the latest follow-up.
The combination of ibrutinib with venetoclax was well
tolerated in relapsed and refractory CLL. There were no
significant additional AEs with the combination compared
with published data on either drug alone. In particular, the
incidence of TLS with the combination was one (2%) of 50
patients, which compares favorably with 10 (18%) of 56
patients for venetoclax monotherapy before the dose ramp-
up but similar to one (2%) of 60 patients when dose ramp-
up was instituted.27 When venetoclax was combined with
rituximab in a phase III trial, six (3.1%) of 194 patients
experienced TLS.29 Therefore, with gradual venetoclax
dose ramp-up and careful monitoring, TLS is manageable,
even when venetoclax is combined with ibrutinib. The other
AEs observed with the combination were as expected with
either drug alone, including bruising and bleeding (seen
with ibrutinib) and neutropenia (seen with venetoclax).
There were two suspected unexpected serious adverse
reactions: pemphigus (grade 3) and abdominal pain
(grade 3). The majority of the other AEs were manageable
without delaying or permanently stopping either therapy.
This is the initial description of the combination of two
therapies that target the key pathophysiologic pathways
seen in relapsed CLL, namely BCR-associated signaling by
ibrutinib and apoptosis through venetoclax targeting of
Bcl-2. Both ibrutinib and venetoclax are active in CLL
with improved survival; however, as monotherapies, both
currently are given until disease progression.26 We have
demonstrated promising efficacy that indicates potent syn-
ergy between ibrutinib and venetoclax for inducing MRD-
negative responses with manageable adverse effects. The
observation that a significant proportion of patients experi-
ence MRD-negative remission indicates that this combina-
tion can be given for a limited period and then stopped after
patients achieve a deep remission. This observation is critical
before taking the MRD-guided approach into larger phase III
trials. Whether the combination leads to permanent disease
eradication in a subset of these patients remains to be seen.
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